PMID- 9246566
OWN - NLM
STAT- MEDLINE
DCOM- 19970929
LR  - 20191024
IS  - 0882-0139 (Print)
IS  - 0882-0139 (Linking)
VI  - 26
IP  - 4
DP  - 1997 Jun
TI  - Transforming growth factor-beta 1 induces antigen-specific unresponsiveness in 
      naive T cells.
PG  - 459-72
AB  - Transforming growth factor-beta 1 (TGF-beta 1) is a cytokine with complex 
      immunomodulatory effects including the ability to inhibit the onset or severity 
      of autoimmune disease. This study was designed to test the possibility that one 
      mechanism by which TGF-beta 1 exerts its immunosuppressive effects is by inducing 
      antigen (Ag)-specific unresponsiveness in CD4+ cells. TGF-beta 1 was shown here 
      to inhibit the Ag-specific proliferation of naive CD4+ cells from T cell receptor 
      (TCR) transgenic mice. More importantly, the naive CD4+ cells exposed to TGF-beta 
      1 and Ag, but not to TGF-beta 1 alone, in primary cultures were unable to 
      proliferate or secrete IL-2 in response to a subsequent Ag challenge following 
      removal of TGF-beta 1 from the cultures. Anti-CD28 mAb partially blocked the 
      Ag-specific inactivation induced by TGF-beta 1 in naive CD4+ cells. The 
      inhibitory effects of TGF-beta 1 on CD4+ cells are not mediated by alterations in 
      APC costimulation since TGF-beta 1 did not inhibit the Ag-induced expression of 
      MHC class II molecules, CD80 or CD86 on splenic APC. Taken together, the results 
      suggest that the immunosuppressive activities of TGF-beta 1 encompass direct 
      induction of Ag-specific unresponsiveness in naive CD4+ cells.
FAU - Gilbert, K M
AU  - Gilbert KM
AD  - University of Arkansas for Medical Sciences, Little Rock 72205, USA.
FAU - Thoman, M
AU  - Thoman M
FAU - Bauche, K
AU  - Bauche K
FAU - Pham, T
AU  - Pham T
FAU - Weigle, W O
AU  - Weigle WO
LA  - eng
GR  - A111576/PHS HHS/United States
GR  - AG09948/AG/NIA NIH HHS/United States
GR  - AG12908/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Immunol Invest
JT  - Immunological investigations
JID - 8504629
RN  - 0 (Antigens)
RN  - 0 (Antigens, CD)
RN  - 0 (B7-1 Antigen)
RN  - 0 (B7-2 Antigen)
RN  - 0 (Cd86 protein, mouse)
RN  - 0 (Histocompatibility Antigens Class II)
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (Interleukin-2)
RN  - 0 (Membrane Glycoproteins)
RN  - 0 (Receptors, Antigen, T-Cell)
RN  - 0 (Transforming Growth Factor beta)
SB  - IM
MH  - Animals
MH  - Antigens
MH  - Antigens, CD/metabolism
MH  - B7-1 Antigen/metabolism
MH  - B7-2 Antigen
MH  - CD4-Positive T-Lymphocytes/*drug effects/*immunology
MH  - Cells, Cultured
MH  - Histocompatibility Antigens Class II/metabolism
MH  - Immune Tolerance
MH  - Immunosuppressive Agents/pharmacology
MH  - Interleukin-2/metabolism
MH  - Lymphocyte Activation
MH  - Male
MH  - Membrane Glycoproteins/metabolism
MH  - Mice
MH  - Mice, Inbred A
MH  - Mice, Transgenic
MH  - Receptors, Antigen, T-Cell/genetics/metabolism
MH  - Transforming Growth Factor beta/*pharmacology/physiology
EDAT- 1997/06/01 00:00
MHDA- 1997/06/01 00:01
CRDT- 1997/06/01 00:00
PHST- 1997/06/01 00:00 [pubmed]
PHST- 1997/06/01 00:01 [medline]
PHST- 1997/06/01 00:00 [entrez]
AID - 10.3109/08820139709022702 [doi]
PST - ppublish
SO  - Immunol Invest. 1997 Jun;26(4):459-72. doi: 10.3109/08820139709022702.